solute carrier family 25 member 23Genealiases: APC2 · MCSC2 · SCAMC3 · SCaMC-3
Q-omics provides the consensus-scored SLC25A23 profile across patient tissues and cancer cell-line models. SLC25A23 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC25A23 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SLC25A23 protein abundance shows 26,809 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where SLC25A23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A23 survival associations across molecular data types. SLC25A23 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A23 RNA expression–survival associations across cancer types. High SLC25A23 expression shows unfavorable associations in UCEC, ACC and SKCM, but favorable associations in KIRC, HNSC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC25A23 RNA expression.
This table summarizes SLC25A23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A23 shows lower tumor expression in HNSC, BLCA, COAD, THCA and READ and higher tumor expression in LIHC. The HNSC box plot shows higher SLC25A23 RNA expression in normal versus tumor tissue (log2 FC = −1.283, t-test p < 0.001).
This table shows molecular features associated with SLC25A23 in patient tissues and cancer cell lines. In patient samples, SLC25A23 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and SOFT_TISSUE.
